REG - Craneware plc - Transaction in Own Shares

CranewareAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260413:nRSM1488Aa&default-theme=true

RNS Number : 1488A  Craneware plc  13 April 2026

 13 April 2026

Craneware plc

("Craneware" or the "Company" or the "Group")

 

Transaction in Own Shares

 

Craneware (AIM: CRW.L), a leader in healthcare financial performance
solutions, announces today it has purchased the following number of its
Ordinary Shares of 1 pence each through Investec Bank plc ("Investec") in the
period from 7 April 2026 to 9 April 2026.

The table below contains detailed information about the purchases made as part
of the buyback programme which was announced by the Company on 16 March 2026
(the "Programme").

 Date           Venue  Volume-weighted average price (p)  Aggregated volume  Lowest price per share (p)  Highest price per share (p)
 07 April 2026  AIMX   1384.0000                          3,778              1384.0000                   1384.0000
 07 April 2026  XLON   1374.3312                          1,703              1344.0000                   1384.0000
 09 April 2026  AIMX   1390.7159                          24,731             1374.0000                   1402.0000
 09 April 2026  XLON   1391.8684                          10,519             1374.0000                   1422.0000

 

The Company intends to hold the purchased shares in Treasury.

 

Following the above transactions, the Company will hold 580,290 Ordinary
Shares in Treasury and has 34,961,879 Ordinary Shares in issue (excluding
Treasury shares).

 

The figure of 34,961,879 represents the total voting rights in the Company and
may be used by shareholders as the denominator for calculating whether they
are required to notify their interest in, or a change to their interest in,
the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Individual Transactions

In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No
596/2014 as it forms part of UK law, a full breakdown of the individual trades
made by Investec on behalf of the Company as part of the buyback programme is
attached to this announcement.

http://www.rns-pdf.londonstockexchange.com/rns/1488A_1-2026-4-12.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/1488A_1-2026-4-12.pdf)

 

For further information please contact:

 Craneware plc                                    +44 (0)131 550 3100
 Keith Neilson, CEO
 Craig Preston, CFO

 Alma Strategic Communications                    +44 (0)20 3405 0205
 Caroline Forde, Kinvara Verdon, Louisa El-Ahwal  craneware@almastrategic.com

 

About Craneware

For over 25 years, The Craneware Group (AIM:CRW.L) has been a leader in
healthcare financial and operational transformation, delivering cutting-edge
technologies that drive measurable impact. Our Trisus(®) cloud ecosystem
unifies data, revenue intelligence, margin intelligence, and advanced
analytics, enabling healthcare organizations to optimize performance, improve
financial sustainability, and drive strategic growth. As a trusted Microsoft
partner, we provide future-ready solutions-including the Best in KLAS Trisus
Chargemaster - that simplify the complexities of healthcare finance and
operations. What sets us apart is our unique combination of deep healthcare
expertise and engineering excellence, positioning us as a strategic partner
rather than just a technology provider. The Craneware Group empowers
healthcare organizations to achieve sustainable financial success while
delivering better outcomes for the communities they serve - today and in the
future. Together, we are transforming the business of healthcare.

 

Learn more at www.thecranewaregroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSGPURWCUPQGRP



            Copyright 2019 Regulatory News Service, all rights reserved